Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 53.68M | 49.63M | 42.00M | 28.65M | 6.27M | 2.27M |
Gross Profit | 25.05M | 22.58M | 4.61M | 3.21M | -1.18M | 1.10M |
EBITDA | 3.60M | 5.39M | 5.35M | 4.38M | -2.97M | -1.22M |
Net Income | -1.79M | -1.52M | 55.37K | 1.43M | -3.65M | -1.25M |
Balance Sheet | ||||||
Total Assets | 64.81M | 48.69M | 48.46M | 26.16M | 19.57M | 3.42M |
Cash, Cash Equivalents and Short-Term Investments | 30.31M | 19.34M | 24.80M | 8.61M | 12.33M | 1.11M |
Total Debt | 2.65M | 2.19M | 2.19M | 2.33M | 780.98K | 0.00 |
Total Liabilities | 16.92M | 12.77M | 12.54M | 9.40M | 4.50M | 714.00K |
Stockholders Equity | 47.89M | 35.92M | 35.92M | 16.76M | 15.07M | 2.65M |
Cash Flow | ||||||
Free Cash Flow | 1.21M | -3.94M | -1.12M | -2.28M | -3.85M | -2.16M |
Operating Cash Flow | 9.43M | 3.58M | 4.26M | 4.97M | -1.00M | -1.44M |
Investing Cash Flow | -18.38M | -7.52M | -17.37M | -7.24M | -3.17M | -839.00K |
Financing Cash Flow | 9.86M | -1.47M | 17.34M | -1.44M | 15.38M | 2.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | AU$7.56M | 47.78 | -2.18% | ― | -2.13% | 81.58% | |
59 Neutral | ― | -4.25% | ― | 14.44% | -2450.00% | ||
50 Neutral | AU$1.47B | 2.06 | -28.25% | 3.11% | 16.21% | -7.40% | |
47 Neutral | AU$27.42M | ― | -54.77% | ― | -14.50% | -77.33% | |
46 Neutral | AU$10.38M | ― | ― | 16.26% | 62.58% | ||
42 Neutral | AU$29.81M | ― | -31.58% | ― | 22.29% | 64.62% | |
36 Underperform | AU$11.64M | ― | -347.17% | ― | -5.53% | -50.00% |
Acusensus Ltd announced the cessation of 22,698 performance rights due to the conditions for these securities not being met or becoming incapable of being satisfied. This cessation may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s operational performance and strategic direction.
The most recent analyst rating on (AU:ACE) stock is a Buy with a A$1.23 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd has announced the quotation of 190,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective June 4, 2025. This move is part of the company’s strategy to enhance its market presence and operational capacity, potentially impacting its industry positioning by increasing its capital for future growth and development.
The most recent analyst rating on (AU:ACE) stock is a Buy with a A$1.30 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.